







CLAIMS

1. Use of a compound of Formula (I), or a pharmaceutically acceptable salt thereof, in the preparation of a medicament for ameliorating or treating a viral infection, wherein the compound of Formula (I) has the structure:



(I)

wherein:




B^{1A} is , , , , ,  or , wherein R^{B2} can be NH_2; R^{G2} is an optionally substituted C_{1-6} alkyl; and R^{H2} is hydrogen or NH_2;

R^{3A} is selected from the group consisting of OH, –OC(=O)R"^{A} and an optionally substituted O-linked α-amino acid;

R^{4A} is halogen;



R^{a1} and R^{a2} are independently hydrogen or deuterium;


R^{A} is hydrogen or deuterium;

R^{1A} is selected from the group consisting of hydrogen, an optionally substituted acyl, an optionally substituted O-linked α-amino acid, ,  and ;

R^{2A} is azido, $-(CH_2)_{1-6}$halogen or $-(CH_2)_{1-6}N_3$;

R^{5A} is hydrogen or halogen;

R^{6A}, R^{7A} and R^{8A} are independently selected from the group consisting of absent, hydrogen,  and ; or

R^{6A} is  and R^{7A} is absent or hydrogen;

R^{8A} is an optionally substituted aryl;

R^{9A} is N-alanine, N-valine, N-leucine, N-alanine isopropyl ester, N-alanine cyclohexyl ester, N-alanine neopentyl ester, N-valine isopropyl ester or N-leucine isopropyl ester;

R^{10A} and R^{11A} are independently N-alanine, N-valine, N-leucine, N-alanine isopropyl ester, N-alanine cyclohexyl ester, N-alanine neopentyl ester, N-valine isopropyl ester or N-leucine isopropyl ester;

R^{12A} and R^{13A} are independently absent or hydrogen;

R^{14A} is O^- or OH;

R^{22A} and R^{23A} are each hydrogen;

R^{24A} is selected from the group consisting of hydrogen, an optionally substituted C_{1-24} alkyl, and an optionally substituted $-O-C_{1-24}$ alkyl;

R^{25A} is an optionally substituted C_{1-24} alkyl;

$R^{"A}$ is an optionally substituted C_{1-24} alkyl;

m is 0 or 1;

w is 0;

s is 0, 1, 2 or 3; and

Z^{1A}, Z^{2A}, Z^{3A} and Z^{4A} are each O;

wherein the viral infection is caused by a Filoviridae virus; and

when a group is substituted, the group is substituted with one or more substituents selected from the group consisting of alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, heteroaryl, heterocyclyl, aryl(alkyl), heteroaryl(alkyl), (heterocyclyl)alkyl, hydroxy, alkoxy,

acyl, cyano, halogen, thiocarbonyl, O-carbamyl, N-carbamyl, O-thiocarbamyl, N-thiocarbamyl, C-amido, N-amido, S-sulfonamido, N-sulfonamido, C-carboxy, O-carboxy, isocyanato, thiocyanato, isothiocyanato, nitro, azido, silyl, sulfenyl, sulfinyl, sulfonyl, haloalkyl, haloalkoxy, trihalomethanesulfonyl, trihalomethanesulfonamido, an amino, a mono-substituted amino group and a di-substituted amino group; and

wherein an –N–linked α-amino acid ester derivative refers to an α-amino acid in which a main-chain carboxylic acid group has been converted to an ester group.

2. The use of Claim 1, wherein the Filoviridae virus is Ebolavirus.

3. The use of Claim 2, wherein the Ebolavirus is selected from the group consisting of Ebola virus (EBOV), Reston ebolavirus (REBOV), Sudan ebolavirus (SEBOV), Taï Forest ebolavirus (TAFV) and Bundibugyo ebolavirus (BEBOV).

4. The use of Claim 1, wherein the Filoviridae virus is Marburgvirus.

5. The use of Claim 4, wherein the Marburgvirus is selected from the group consisting of Marburg virus (MARV) and Ravn virus (RAVV).

6. The use of any one of Claims 1-5, wherein R^{2A} is $-(CH_2)_{1-6}Cl$.

7. The use of Claim 6, wherein R^{2A} is chloromethyl.

8. The use of any one of Claims 1-5, wherein R^{2A} is azido.

9. The use of any one of Claims 1-5, wherein R^{2A} is $-(CH_2)_{1-6}N_3$.

10. The use of Claim 9, wherein R^{2A} is azidomethyl.

11. The use of any one of Claims 1-10, wherein the R^{4A} is F.

12. The use of any one of Claims 1-10, wherein the R^{4A} is Cl.


13. The use of any one of Claims 1-12, wherein R^{5A} is hydrogen.


14. The use of any one of Claims 1-12, wherein R^{5A} is halogen.


15. The use of any one of Claims 1-14, wherein R^{1A} is hydrogen.

16. The use of any one of Claims 1-14, wherein R^{1A} is an optionally substituted acyl.


17. The use of any one of Claims 1-14, wherein R^{1A} is an optionally substituted O-linked α-amino acid.


18. The use of any one of Claims 1-14, wherein R^{1A} is .


19. The use of Claim 18, wherein R^{6A} is , R^{7A} is absent or hydrogen; and m is 0.

20. The use of Claim 18, wherein R^{6A} is , R^{7A} is absent or hydrogen; and m is 1.

21. The use of Claim 18, wherein R^{6A} and R^{7A} are independently absent or hydrogen.

22. The use of Claim 18, wherein R^{6A} and R^{7A} are each .



23. The use of Claim 18, wherein R^{6A} and R^{7A} are each .


24. The use of any one of Claims 1-14, wherein R^{1A} is .

25. The use of Claim 24, wherein R^{8A} is an optionally substituted phenyl.




26. The use of Claim 24, wherein R^{8A} is an optionally substituted naphthyl.

27. The use of any one of Claims 24-26, wherein R^{9A} is N-alanine isopropyl ester, N-alanine cyclohexyl ester, N-alanine neopentyl ester, N-valine isopropyl ester or N-leucine isopropyl ester.

28. The use of any one of Claims 24-26, wherein R^{9A} is selected from the group consisting of , , and .

29. The use of any one of Claims 1-14, wherein R^{1A} is .

30. The use of Claim 29, wherein R^{10A} and R^{11A} are independently N-alanine isopropyl ester, N-alanine cyclohexyl ester, N-alanine neopentyl ester, N-valine isopropyl ester or N-leucine isopropyl ester.

31. The use of Claim 29, wherein R^{10A} and R^{11A} are independently selected from the group consisting of , , and .

32. The use of any one of Claims 1-31, wherein R^{3A} is OH.

33. The use of any one of Claims 1-31, wherein R^{3A} is $-OC(=O)R"^{A}$.

34. The use of Claim 33, wherein R"A is an unsubstituted C_{1-24} alkyl.


35. The use of any one of Claims 1-31, wherein R^{3A} is an optionally substituted O-linked α-amino acid.


36. The use of any one of Claims 1-35, wherein R^{A} is hydrogen.


37. The use of any one of Claims 1-35, wherein R^{A} is deuterium.


38. The use of any one of Claims 1-37, wherein R^{a1} and R^{a2} are both hydrogen.


39. The use of any one of Claims 1-37, wherein R^{a1} and R^{a2} are both deuterium.


40. The use of any one of Claims 1-39, wherein B^{1A} is  .


41. The use of any one of Claims 1-39, wherein B^{1A} is  .

42. The use of any one of Claims 1-39, wherein B^{1A} is  .





43. The use of any one of Claims 1-39, wherein B^{1A} is  .




44. The use of any one of Claims 1-39, wherein B^{1A} is  .

45. The use of any one of Claims 1-39, wherein B^{1A} is  .












46. The use of any one of Claims 1-39, wherein B^{1A} is  .

47. The use of any one of Claims 1-5, wherein the compound is selected from the group consisting of:













 ,  ,  ,  ,










 ,  and  , or a pharmaceutically acceptable salt of any of the foregoing.


48. The use of any one of Claims 1-5, wherein the compound is selected from the group consisting of:


,

,

,

,

,

,

,

,

,

and

, or a pharmaceutically acceptable salt of any of the foregoing.


49. The use of any one of Claims 1-5, wherein the compound is selected from the group consisting of:


,

,

,

,

,

,

,

,

,

,

,

,



,

,

,

,

,

,

,

,

,




,




,




,




,




,




,













,














,
















,


,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

and

, or a pharmaceutically acceptable salt of any of the foregoing.

50. The use of any one of Claims 1-5, wherein the compound is selected from the group consisting of:


,

,

,

,

,

,

,

,

,

,


,

and

, or a pharmaceutically acceptable salt of any of the foregoing.

51. The use of any one of Claims 1-50, further comprising the use of an interferon.

52. The use of Claim 51, wherein the interferon is a pegylated interferon.

53. The use of any one of Claims 51-52, wherein the interferon is a Type 1 interferon.

54. The use of Claim 53, wherein the Type 1 interferon is an alpha-interferon (IFN-α).

55. The use of Claim 54, wherein the IFN-α is selected from the group consisting of Pegylated interferon-alpha-2a (PEGASYS®), Pegylated interferon-alpha-2b (PEG-INTRON®) and interferon alfacon-1 (INFERGEN®).

56. The use of Claim 53, wherein the interferon is a beta-interferon (IFN-β).

57. The use of any one of Claims 51-52, wherein the interferon is a Type 2 interferon.

58. The use of any one of Claims 51-52, wherein the interferon is a Type 3 interferon.

59. The use of Claim 58, wherein the Type 3 interferon is a lambda-interferon (IFN-λ).

60. The use of Claim 59, wherein the IFN-λ is pegylated interferon lambda.

61. The use of any one of Claims 1-60, wherein the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is used in combination with a compound selected from the group consisting of ribavirin, (2S,3S,4R,5R)-2-(4-amino-5H-pyrrolo[3,2-d]pyrimidin-7-yl)-5-(hydroxymethyl)pyrrolidine-3,4-diol, 5-Fluoro-2-oxo-1H-pyrazine-3-carboxamide,

hexadecyloxypropyl-cidofovir, AVI-7537, AVI-7288, ZMapp and TKM-Ebola, or a pharmaceutically acceptable salt of any of the foregoing.